Evidence map›Paper›PMID 33686657›Full record

ArticleBritish journal of pharmacology2021

The effect of 5-HT

Sergio Vegas-Suárez, Asier Aristieta, Catalina Requejo, Harkaitz Bengoetxea, José Vicente Lafuente, Cristina Miguelez, Luisa Ugedo

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. The effect of 5-HTBritish journal of pharmacology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sergio Vegas-SuárezDepartment of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain.
Asier AristietaDepartment of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, USA.
Catalina RequejoLaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), Leioa, Spain.
Harkaitz BengoetxeaLaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), Leioa, Spain.
José Vicente LafuenteLaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), Leioa, Spain.
Cristina MiguelezDepartment of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain.
Luisa UgedoDepartment of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain.
University of the Basque Country · ESBioCruces Health research Institute · ESCenter for the Neural Basis of Cognition · US

Funding

Basque Government PIBA 2019-38Basque Government T747-13Euskal Herriko Unibertsitatea GIU19/092Spanish Ministry of Economy and Competitiveness SAF2016-77758-R AEI/FEDER, UE
6 · The paper itself

Abstract

background and purposel-DOPA prolonged treatment leads to disabling motor complications as dyskinesia that could be decreased by drugs acting on 5-HT EXPERIMENTAL APPROACH: Extracellular single-unit electrocorticogram and local field potential recordings under anaesthesia, immunostaining assays and optogenetic manipulation coupled to electrophysiological recordings were performed. KEY

resultsSystemic buspirone reduced the entopeduncular nucleus firing rate in the sham animals and burst activity in the 6-OHDA-lesioned rats (with or without l-DOPA treatment), while local administration reduced entopeduncular nucleus activity in all the groups, regardless of DA integrity. Systemic 8-OH-DPAT also induced inhibitory effects only in the sham animals. Effects triggered by buspirone and 8-OH-DPAT were reversed by the 5-HT CONCLUSION AND IMPLICATIONS: Systemic 5-HT

Indexed as

Entopeduncular NucleusReceptor, Serotonin, 5-HT1A8-Hydroxy-2-(di-n-propylamino)tetralinAnimalsBuspironeLevodopaOxidopamineRatsRats, Sprague-Dawley8-Hydroxy-2-(di-n-propylamino)tetralinBuspironeLevodopaOxidopamineReceptor, Serotonin, 5-HT1A5-hyroxytryptamine8-OH-DPATbasal gangliabuspironedyskinesiaelectrophysiologyParkinson's diseaseserotonin

Identifiers

PMID33686657
PMCPMC8252460
OpenAlexW3133820243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.